Abstract PO1-27-01: Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase 3 TrialQingyuan Zhang, Qingshan Li, Yu Ren et al.|Cancer Research|2024Cited by 0
[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex<sup>®</sup> for patients with premenopausal breast cancer].Xinyu Shao, Zefei Jiang, Qinxin Zhang et al.|PubMed|2025Cited by 0